180 Life Sciences - Warrants (07/11/2025) EBIT

The latest EBIT for ATNFW is $-9.8B as of June 2026. That compares with $-9.6M in the prior-year period — down 101863.4% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside 180 Life Sciences - Warrants (07/11/2025)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, ATNFW's EBIT moved from $-9.6M to $-9.8B — a 101863.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in 180 Life Sciences - Warrants (07/11/2025)'s operating scale or balance-sheet position.

Against Healthcare companies, ATNFW currently prints $-9.8B for EBIT, while the sector average sits near $23B. That is roughly 142.8% below the sector mean. Large gaps often invite a closer look at 180 Life Sciences - Warrants (07/11/2025)'s growth, margins, and balance sheet.

A EBIT figure of $-9.8B for ATNFW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting ATNFW's EBIT ($-9.8B), review year-over-year change from $-9.6M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.